

## DAFTAR PUSTAKA

- Abobaker, A., Nagib, T. and Alsoufi, A. (2021) ‘The impact of certain genetic variants (single nucleotide polymorphisms) on incidence and severity of COVID-19’, *Journal of Gene Medicine*, 23(2). Available at: <https://doi.org/10.1002/jgm.3310>.
- Anwar Daud, Aminuddin Syam, A.Arsunan Arsin and Sudirman Sanuddin (2020) *Penanganan COVID-19 Ditinjau Dari Perspektif Kesehatan Masyarakat*, Gosyen Publishing
- Ardiani, H.E., Permatasari, T.A.E. and Sugiati, S. (2021) ‘Obesitas, Pola Diet, dan Aktifitas Fisik dalam Penanganan Diabetes Melitus pada Masa Pandemi Covid-19’, *Muhammadiyah Journal of Nutrition and Food Science (MJNF)*, 2(1), p. 1. Available at: <https://doi.org/10.24853/mjnf.2.1.1-12>.
- Banday, A.R. *et al.* (2022) ‘Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries’, *Nature Genetics*, 54(8), pp. 1103–1116. Available at: <https://doi.org/10.1038/s41588-022-01113-z>.
- Bonnevie-Nielsen, V. *et al.* (2005) ‘Variation in antiviral 2',5'-oligoadenylate synthetase (2'5'AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene’, *American Journal of Human Genetics*, 76(4), pp. 623–633. Available at: <https://doi.org/10.1086/429391>.
- Bourgonje, A.R. *et al.* (2020) ‘Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)’, *Journal of Pathology*, 251(3), pp. 228–248. Available at: <https://doi.org/10.1002/path.5471>.
- Burhan, E. *et al.* (2022) *Cedera miokardium pada infeksi COVID-19, Pedoman tatalaksana COVID-19 edisi 4*.
- Das, S.K. (no date) ‘The Pathophysiology, Diagnosis and Treatment of Corona Virus Disease 2019 (COVID-19)’. Available at: <https://doi.org/10.1007/s12291-020-00919-0>.
- Djalante, R. *et al.* (2020) ‘Review and analysis of current responses to COVID-19 in Indonesia: Period of January to March 2020’, *Progress in Disaster Science*, 6. Available at: <https://doi.org/10.1016/j.pdisas.2020.100091>.
- Dyer, O. (2021) ‘Covid-19: Indonesia becomes Asia’s new pandemic epicentre as delta variant spreads’, *BMJ (Clinical research ed.)*, 374(July), p. n1815. Available at: <https://doi.org/10.1136/bmj.n1815>.

- Endeshaw, Y. and Campbell, K. (2022) 'Advanced age, comorbidity and the risk of mortality in COVID-19 infection', *Journal of the National Medical Association*, 114(5), pp. 512–517. Available at: <https://doi.org/10.1016/j.jnma.2022.06.005>.
- Garcin, E.D. (2019) 'GAPDH as a model non-canonical AU-rich RNA binding protein', *Seminars in Cell and Developmental Biology*. Elsevier Ltd, pp. 162–173. Available at: <https://doi.org/10.1016/j.semcd.2018.03.013>.
- Hamano, E. *et al.* (2005) 'Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population', *Biochemical and Biophysical Research Communications*, 329(4), pp. 1234–1239. Available at: <https://doi.org/10.1016/j.bbrc.2005.02.101>.
- Harrison, A.G., Lin, T. and Wang, P. (2020) 'Mechanisms of SARS-CoV-2 Transmission and Pathogenesis', *Trends in Immunology*, 41(12), pp. 1100–1115. Available at: <https://doi.org/10.1016/j.it.2020.10.004>.
- Hendaus, M.A. and Jomha, F.A. (2021) 'Delta variant of COVID-19: A simple explanation', *Qatar Medical Journal*, 2021(3), pp. 1–5. Available at: <https://doi.org/10.5339/qmj.2021.49>.
- Hornung, V. *et al.* (2014) 'OAS proteins and cGAS: Unifying concepts in sensing and responding to cytosolic nucleic acids', *Nature Reviews Immunology*, 14(8), pp. 521–528. Available at: <https://doi.org/10.1038/nri3719>.
- Ikawaty, R. (2020) 'Dinamika Interaksi Reseptor ACE2 dan SARS-CoV-2 Terhadap Manifestasi Klinis COVID-19', *KELUWIH: Jurnal Kesehatan dan Kedokteran*, 1(2), pp. 70–76. Available at: <https://doi.org/10.24123/kesdok.v1i2.2869>.
- Joanna A. Pulit-Penalzoza, Svetlana V. Scherbik, and M.A.B. (2013) 'Activation of Oas1a gene expression by type I IFN requires both STAT1 and STAT2 while only STAT2 is required for Oas1b activation', *virology journal*, 425(2), pp. 71–81. Available at: <https://doi.org/10.1016/j.virol.2011.11.025>.Activation.
- Jose, R.J. and Manuel, A. (2020) 'COVID-19 cytokine storm: the interplay between inflammation and coagulation', *The Lancet Respiratory Medicine*, 8(6), pp. e46–e47. Available at: [https://doi.org/10.1016/S2213-2600\(20\)30216-2](https://doi.org/10.1016/S2213-2600(20)30216-2).
- Kuldeep, D. *et al.* (2020) 'Update on COVID-19', *Clinical Microbiology Reviews*, 33(4), pp. 1–48.
- Kumar, A. *et al.* (2021) 'SARS-CoV-2-specific virulence factors in COVID-19', *Journal of Medical Virology*, 93(3), pp. 1343–1350. Available at: <https://doi.org/10.1002/jmv.26615>.

- Lepelletier.D, Grandbastien B, Michael J. Smart, R.B.N. (2020) ‘Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-’, *Ann Oncol*, (January), pp. 19–21.
- Li, X. (2016) ‘OAS-a new player in controlling antiviral innate immunity’, *Physiology & behavior*, 176(3), pp. 139–148. Available at: <https://doi.org/10.1016/j.coviro.2015.01.010.OASL>.
- Li, Y. *et al.* (2019) ‘Erratum: Activation of RNase L is dependent on OAS3 expression during infection with diverse human viruses (Proceedings of the National Academy of Sciences of the United States of America (2016) 113 (2241–2246) DOI: 10.1073/pnas.1815735116). (Proc. Natl. ’, *Proceedings of the National Academy of Sciences of the United States of America*, 116(25), p. 12573. Available at: <https://doi.org/10.1073/pnas.1908765116>.
- Lim, S. *et al.* (2021) ‘COVID-19 and diabetes mellitus: from pathophysiology to clinical management’, *Nature Reviews Endocrinology*, 17(1), pp. 11–30. Available at: <https://doi.org/10.1038/s41574-020-00435-4>.
- Liu, X. *et al.* (2017) ‘A functional variant in the OAS1 gene is associated with Sjögren’s syndrome complicated with HBV infection’, *Scientific Reports*, 7(1), pp. 1–9. Available at: <https://doi.org/10.1038/s41598-017-17931-9>.
- Luknis S, Sutanto P (2018) *Statistik Kesehatan ,Depok :PT Raja Grafindo Persada.*
- Menteri Hukum Dan Hak Asasi Manusia Republik Indonesia. *Peraturan Presiden Republik Indonesia Nomor 88 Tahun 2021 Tentang Strategi Nasional Kelanjutusiaan.*
- Nicholls, C., Li, H. and Liu, J.P. (2012) ‘GAPDH: A common enzyme with uncommon functions’, *Clinical and Experimental Pharmacology and Physiology*, pp. 674–679. Available at: <https://doi.org/10.1111/j.1440-1681.2011.05599.x>.
- Pairo-Castineira, E. *et al.* (2021) ‘Genetic mechanisms of critical illness in COVID-19’, *Nature*, 591(7848), pp. 92–98. Available at: <https://doi.org/10.1038/s41586-020-03065-y>.
- Purwo Setiyo Nugroho (2020), *Analisis Data Penelitian Bidang Kesehatan: Gosyen Publishing*
- Rauf, A. *et al.* (2020) ‘COVID-19 Pandemic : Epidemiology , Etiology , Conventional and Non-Conventional Therapies’.

- Ren, L.L. *et al.* (2020) 'Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study', *Chinese medical journal*, 133(9), pp. 1015–1024. Available at: <https://doi.org/10.1097/CM9.0000000000000722>.
- Rios, J.J. *et al.* (2007) 'Characterization of the equine 2'-5' oligoadenylate synthetase 1 (OAS1) and ribonuclease L (RNASEL) innate immunity genes', *BMC Genomics*, 8, pp. 1–14. Available at: <https://doi.org/10.1186/1471-2164-8-313>.
- Sams, A.J. *et al.* (2016) 'Adaptively introgressed Neandertal haplotype at the OAS locus functionally impacts innate immune responses in humans', *Genome Biology*, 17(1), pp. 1–15. Available at: <https://doi.org/10.1186/s13059-016-1098-6>.
- Sánchez-González, M.T. *et al.* (2021) 'Prevalence of the SNP rs10774671 of the OAS1 gene in Mexico as a possible predisposing factor for RNA virus disease.', *International journal of molecular epidemiology and genetics*, 12(3), pp. 52–60. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/34336138> <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC8310884>.
- Seidler, N.W. (2013) 'Compartmentation of GAPDH', *Advances in Experimental Medicine and Biology*, 985, pp. 61–101. Available at: [https://doi.org/10.1007/978-94-007-4716-6\\_3](https://doi.org/10.1007/978-94-007-4716-6_3).
- Setiawati, S. and K.Azwar, M. (2020) 'COVID-19 and Indonesia', *Acta medica Indonesiana*, 52(1), pp. 84–89. Available at: <https://pubmed.ncbi.nlm.nih.gov/32291377/>.
- Sugiyono (2017) *Statistika Untuk Penelitian*. Bandung: Alfabeta.
- Sutanto Priyo Hastono (2016) *Analisis Data Pada Bidang Kesehatan*, Depok: PT Raja Grafindo Persada.
- Shereen, M.A. *et al.* (2020) 'COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses', *Journal of Advanced Research*, 24, pp. 91–98. Available at: <https://doi.org/10.1016/j.jare.2020.03.005>.
- Shiehzadegan, S. *et al.* (2021) 'Analysis of the Delta Variant B.1.617.2 COVID-19', *Clinics and Practice*, 11(4), pp. 778–784. Available at: <https://doi.org/10.3390/clinpract11040093>.
- Shigemura, J. *et al.* (2020) 'Public responses to the novel 2019 coronavirus (2019-nCoV) in Japan: Mental health consequences and target populations', *Psychiatry and Clinical Neurosciences*, 74(4), pp. 281–282. Available at: <https://doi.org/10.1111/pcn.12988>.

- Soveg, F.W. *et al.* (2021) 'Endomembrane targeting of human OAS1 p46 augments antiviral activity', *eLife*, 10. Available at: <https://doi.org/10.7554/ELIFE.71047>.
- Soy, M. *et al.* (2020) 'Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment', *Clinical Rheumatology*, 39(7), pp. 2085–2094. Available at: <https://doi.org/10.1007/s10067-020-05190-5>.
- Wal, J.M. (2001) 'Risk evaluation and prevention', *Cahiers de Nutrition et de Di t tique*, 36(4), pp. 263–266.
- Wang, M. and Casey, P.J. (2016) 'Protein prenylation: Unique fats make their mark on biology', *Nature Reviews Molecular Cell Biology*, 17(2), pp. 110–122. Available at: <https://doi.org/10.1038/nrm.2015.11>.
- Wasityastuti, W., Dhamarjati, A. and Siswanto (2019) 'Imunosenesens dan Kerentanan Populasi Usia Lanjut Terhadap Coronavirus Disease 2019 (Covid-19)', *Respirologi Indonesia*, 40(3), pp. 182–191.
- Wulandari, L. *et al.* (2021) 'Initial study on TMPRSS2 p.Val160Met genetic variant in COVID-19 patients', *Human Genomics*, 15(1), pp. 1–9. Available at: <https://doi.org/10.1186/s40246-021-00330-7>.
- Zeberg, H. and P  bo, S. (2021) 'A genomic region associated with protection against severe COVID-19 is inherited from Neandertals', *Proceedings of the National Academy of Sciences of the United States of America*, 118(9), pp. 3–7. Available at: <https://doi.org/10.1073/pnas.2026309118>.
- Zhou, S. *et al.* (2021) 'A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity', *Nature Medicine*, 27(4), pp. 659–667. Available at: <https://doi.org/10.1038/s41591-021-01281-1>.
- Zhu, J. *et al.* (2015) 'Antiviral activity of human oligoadenylate synthetases-like (OASL) is mediated by enhancing retinoic acid-inducible gene I (RIG-I) signaling', *immunity jurnal*, 40(6), pp. 936–948. Available at: <https://doi.org/10.1016/j.immuni.2014.05.007>.Antiviral.
- Zhu, N. *et al.* (2020) 'A Novel Coronavirus from Patients with Pneumonia in China, 2019', *New England Journal of Medicine*, 382(8), pp. 727–733. Available at: <https://doi.org/10.1056/nejmoa2001017>.